missing translation for 'onlineSavingsMsg'
Learn More
Learn More
SIGLEC7 Monoclonal Antibody (OTI1A1), TrueMAB™, OriGene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA507377
This item is not returnable.
View return policy
Description
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- and alpha-2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro).Specifications
| SIGLEC7 | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| Q9Y286 | |
| SIGLEC7 | |
| Full length human recombit protein of human SIGLEC7 produced in HEK293T cell. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG1 |
| Western Blot | |
| OTI1A1 | |
| Unconjugated | |
| SIGLEC7 | |
| AIRM1, CD328, CDw328, D-siglec, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2, p75, p75/AIRM1 | |
| Mouse | |
| Affinity Chromatography | |
| RUO | |
| 27036 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction